→ Af­ter watch­ing its Eu­ro­pean share price surge {$ABLX BB} yes­ter­day on pos­i­tive Phase III da­ta, Abl­ynx feels it’s per­fect tim­ing for an IPO on Nas­daq. The Bel­gian biotech is look­ing to raise around $150 mil­lion at a time a grow­ing num­ber of Eu­ro­pean biotechs have been find­ing a warm wel­come on the ex­change. The group is push­ing a new drug for ac­quired throm­bot­ic throm­bo­cy­topenic pur­pu­ra, or aTTP.

→ An in­creas­ing­ly liti­gious Shire has now sued Al­ler­gan, claim­ing the ri­val vi­o­lat­ed an­titrust laws in block­ing pa­tients from re­ceiv­ing its dry eye dis­ease drug.

→ In­tra-Cel­lu­lar Ther­a­pies $IT­CI has raised $150 mil­lion from the sale of stock.

The US Solicitor General is calling on the Supreme Court to take up a fiercely debated case that could have a chilling effect on generic drug companies’ willingness to bring their copycats to market under so-called “skinny” labels, meaning the generic can only be approved for some of the reference product’s indications.

The case in question relates to GSK’s win over Teva in a long-running battle over the generic giant’s skinny label for GSK’s beta-blocker Coreg (carvedilol). At the time in 2007, Teva’s generic label first included two of the three Coreg indications, but Teva did not initially win approval for the third indication for congestive heart failure.

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

The German life science group Sartorius will be picking up French contract manufacturer Polyplus for the price of €2.4 billion, or $2.6 billion.

On Friday, Sartorius announced the acquisition through its French subgroup, Sartorius Stedim Biotech, which will be acquiring Polyplus from private investors Archimed and WP GG Holdings IV. Polyplus has 270 employees and produces materials and components that go into making viral vectors that are used in cell and gene therapies. This includes DNA/RNA reagents as well as plasmid DNA. Polyplus has locations in France, Belgium, China and the US.

Sarissa Capital gained another foothold in its takeover of Amarin with the departure of the Irish drugmaker’s CEO.

Amarin revealed Friday in an SEC filing that Karim Mikhail resigned as president and CEO earlier this week. However, there’s still an ongoing dispute between Mikhail and Amarin, with the now ex-CEO insisting that he has a claim to severance as a result of his resignation. However, Amarin says it disagrees and plans to dispute that claim.